Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-Update.
Ichiro KobayashiShinji AkiokaNorimoto KobayashiNaomi IwataShunichiro TakezakiHaruna NakasekoSatoshi SatoYutaka NishidaTomo NozawaYuichi YamasakiKazuko YamazakiSatoru AraiIchizo NishinoMasaaki MoriPublished in: Modern rheumatology (2020)
Juvenile dermatomyositis is the most common type of juvenile idiopathic inflammatory myopathy mainly affecting the skin and proximal muscles. We have published the Japanese version of 'Clinical practice guidance for juvenile dermatomyositis (JDM) 2018 'consisting of a review of articles in the field and evidence-informed consensus-based experts' opinion on the treatment strategy in collaboration with The Pediatric Rheumatology Association of Japan and The Japan College of Rheumatology under the financial support by 'Research on rare and intractable diseases, Health and Labor Sciences Research Grants'. This article is a digest version of the Japanese guidance.
Keyphrases
- clinical practice
- interstitial lung disease
- disease activity
- systemic sclerosis
- healthcare
- juvenile idiopathic arthritis
- public health
- mental health
- psychometric properties
- systemic lupus erythematosus
- oxidative stress
- randomized controlled trial
- late onset
- risk assessment
- social media
- combination therapy
- replacement therapy
- childhood cancer
- young adults
- human health
- myasthenia gravis